Exchange & Returns Information
Review Details
(0)
| Generic For | PROLIA |
|---|---|
| Active Ingredient | DENOSUMAB |
| Strength | 60MG |
| Manufacturer | ZYDUS CADILA |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 1 VIAL | $ 75.00 | $ 75.00 |
$ 63.75
Apply ZARVY26 (-15%)
You save $ 11.25
|
||
| 2 BOXES - 2 VIALS | $ 79.00 | $ 158.00 |
$ 134.30
Apply ZARVY26 (-15%)
You save $ 23.70
|
||
| ★ Best Value 3 BOXES - 3 VIALS | $ 80.00 | $ 240.00 |
$ 204.00
Apply ZARVY26 (-15%)
You save $ 36.00
|
Reference information will be available soon.
Denoclast 60 is a subcutaneous injection containing denosumab, a fully human monoclonal antibody that targets RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand), a key regulator of osteoclast development and function.
By inhibiting RANKL, Denoclast 60 effectively suppresses bone resorption, enhances bone mass, and reduces the risk of skeletal complications in oncology and osteoporosis settings.
It is a cornerstone agent in the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors, such as breast, prostate, and lung cancer.
Additionally, it is approved for the treatment of giant cell tumor of bone (GCTB) and osteoporosis in high-risk individuals.
The 60 mg formulation is primarily used in non-oncologic indications like postmenopausal osteoporosis and glucocorticoid-induced bone loss, offering biannual dosing convenience with potent anti-resorptive effects.
AntiCancer Drugs > Bone Metastases from Solid Tumors
Used to prevent skeletal-related events (SREs) including pathological fractures, spinal cord compression, and the need for radiation or surgery in patients with bone metastases from solid tumors (e.g., breast, prostate, lung cancer). Denosumab inhibits RANKL, reducing osteoclast-mediated bone degradation.
AntiCancer Drugs > Giant Cell Tumor of Bone (GCTB)
Approved for adults and skeletally mature adolescents with unresectable GCTB or when surgery would lead to severe morbidity. Denosumab controls tumor progression by suppressing the osteoclast-like giant cells surrounding the lesion.
DISEASES/SYMPTOMS > Postmenopausal Osteoporosis
Prescribed for women with a high risk of fractures due to reduced bone mineral density (BMD). Denosumab increases BMD and lowers vertebral, nonvertebral, and hip fracture risk. It is often used when bisphosphonates are contraindicated or poorly tolerated.
DISEASES/SYMPTOMS > Glucocorticoid-Induced Osteoporosis
Indicated for patients undergoing long-term corticosteroid therapy who are at risk of significant bone loss. It helps preserve bone structure and strength in this vulnerable population.
Denosumab functions by selectively binding to and neutralizing RANKL, preventing its interaction with RANK receptors on the surface of osteoclast precursors and mature osteoclasts. This inhibition disrupts the formation, function, and survival of osteoclasts, thereby decreasing bone resorption.
Unlike bisphosphonates, which bind to bone matrix, denosumab acts systemically without accumulation in bone, offering a distinct pharmacokinetic profile. Its reversible mechanism allows for precise control of bone turnover.
Denosumab's anti-resorptive potency is evident across oncologic and non-oncologic applications, providing skeletal protection without renal excretion dependency, making it suitable for patients with renal impairment.
Osteoporosis (Adults)
→ Prolia: 60 mg subcutaneously every 6 months
→ Co-administer with calcium 1000 mg/day and vitamin D ≥400 IU/day
→ Indicated for postmenopausal women, men with osteoporosis, or patients on long-term glucocorticoids
→ Also used in patients undergoing androgen deprivation (prostate cancer) or aromatase inhibitor therapy (breast cancer)
Giant Cell Tumor of Bone (≥13 years, skeletally mature)
→ Initial phase: 120 mg subcutaneously on days 1, 8, and 15
→ Maintenance: 120 mg every 4 weeks thereafter
→ Ensure adequate calcium and vitamin D intake throughout treatment
→ Intended for patients with unresectable tumors or where surgery is not feasible
Bone Metastases from Solid Tumors
→ Xgeva: 120 mg subcutaneously every 4 weeks
→ Supplement with daily calcium and vitamin D
→ Used to prevent skeletal-related complications in metastatic bone disease or multiple myeloma
Hypercalcemia of Malignancy (Bisphosphonate-Refractory)
→ Initial: 120 mg subcutaneously on days 1, 8, and 15
→ Maintenance: 120 mg every 4 weeks
→ Monitor serum calcium closely, especially during initial dosing phase
Administration Guidelines
→ Administer subcutaneously in the upper arm, thigh, or abdomen
→ Rotate injection sites to reduce local irritation
→ Do not shake the pre-filled syringe or vial
→ Ensure patient is calcium and vitamin D replete before initiating therapy
Store in a refrigerator between 2°C and 8°C
Do not freeze
Keep the injection in its original carton to protect from light
If removed from refrigeration, use within 14 days if kept at room temperature (up to 25°C)
Keep out of reach of children
Common: Musculoskeletal pain, fatigue, back pain, constipation, extremity pain
Less Common: Hypocalcemia, skin rash, infections (especially urinary or respiratory tract)
Rare but Serious: Osteonecrosis of the jaw (ONJ), atypical femoral fractures, severe hypocalcemia
Patient Guidance: Report promptly if experiencing jaw pain, thigh/groin pain, or tingling in extremities
No reviews yet. Be the first to review this product!
No combo deals available at the moment.
